Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D76PDV
|
|||
| Drug Name |
BI 425809
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 3 | [1] | |
| Company |
Boehringer Ingelheim
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycine transporter GlyT-1 (SLC6A9) | Target Info | Inhibitor | [2] |
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | NRF2 pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04846868) Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1). U.S. National Institutes of Health. | |||
| REF 2 | Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.